NCT06369727View on ClinicalTrials.gov

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

PHASE1CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

October 15, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

February 15, 2018

Conditions

Erythema

Interventions

DRUG

MOB015B

Topcal formulation

DRUG

MOB015B vehicle

Topcal formulation

DRUG

Negative irritant solution of 0.9% saline

Negative control

Trial Locations (1)

07410

TKL Research, Inc, Fair Lawn

Sponsors

Lead Sponsor

Moberg Pharma AB

All Listed Sponsors

lead

Moberg Pharma AB

INDUSTRY